Extended Data Table 2.
Properties of tested mAbs.
| mAb | Domain (site) | VH usage | Source days after symptom onset | IC50 Wu-Hu-1 (ng/ml) | IC50 Omicron (ng/ml) | PDB/EMD | Ref. |
|---|---|---|---|---|---|---|---|
| sotrovimab | RBD (IV) | 3–23 | SARS-CoV immune | 90.6 | 260 | 6WPS, 7JX3 | 2–4,9,40,62,63 |
| 209 (R346K) | |||||||
| 179 (WA1/2020) |
320 (hCoV-19/USA/WI-WSLH-221686/2021) | ||||||
| VIR-7832* | RBD (IV) | 3–23 | SARS-CoV immune | 53.2 | 165 | 6WPS, 7JX3 | 2–4,9,40,62,63 |
| CT-P59 | RBD (I/RBM) | N/A | SARS-CoV-2 immune | 4.3 | >10’000 | 7CM4 | 64,65 |
| COV2-2130 | RBD (I/RBM) | 3–15 | SARS-CoV-2 immune | 8.1 | 2772 | 7L7E | 36,37 |
| COV2-2196 | RBD (I/RBM) | 1–58 | SARS-CoV-2 immune | 4.3 | >10’000 | 7L7E, 7L7D | 36,37 |
| 2130+2196 | 3.8 | 418 | |||||
| REGN10933 | RBD (I/RBM) | 3–11 | SARS-CoV-2 huIg mice | 8.9 | >10’000 | 6XDG | 31,32,66–68 |
| REGN10987 | RBD (I/RBM) | 3–30 | SARS-CoV-2 immune | 25.1 | >10’000 | 6XDG | 31,32,66–68 |
| 103933+10987 | 7.2 | >10’000 | |||||
| LY-CoV555 | RBD (I/RBM) | 1–69 | SARS-CoV-2 immune | 21.3 | >10’000 | 7KMG | 34,35,69,70 |
| LY-CoV016 | RBD (I/RBM) | 3–66 | SARS-CoV-2 immune | 59.2 | >10’000 | 7C01 | 33 |
| 555+016 | 23 | >10’000 | |||||
| S2D106 | RBD (I/RBM) | 1–69 | Hosp. (98) | 9.1 | >10’000 | 7R7N | 4,38 |
| S2D8 | RBD (I/RBM) | 3–23 | Hosp. (49) | 7.3 | >10’000 | 38 | |
| S2D97 | RBD (I/RBM) | 2–5 | Hosp. (98) | 5.3 | >10’000 | 38 | |
| S2E12 | RBD (I/RBM) | 1–58 | Hosp. (51) | 3.7 | 896 | 7K4N, 7R6X | 4,38,40,44 |
| S2H14 | RBD (I/RBM) | 3–15 | Sympt. (17) | 625 | >10’000 | 7JX3 | 4,12,38 |
| S2H19 | RBD (I/RBM) | 3–15 | Sympt. (45) | 361 | >10’000 | 38 | |
| S2H58 | RBD (I/RBM) | 1–2 | Sympt. (45) | 5.4 | >10’000 | 4,38 | |
| S2H7 | RBD (I/RBM) | 3–66 | Sympt. (17) | 607 | >10’000 | 38 | |
| S2H70 | RBD (I/RBM) | 1–2 | Sympt. (45) | 145 | >10’000 | 38 | |
| S2H71 | RBD (I/RBM) | 2–5 | Sympt. (45) | 10.6 | 993 | 38 | |
| S2M11 | RBD (I/RBM) | 1–2 | Hosp. (46) | 1.0 | >10’000 | 7K43 | 9,38,44 |
| S2N12 | RBD (I/RBM) | 4–39 | Hosp. (51) | 11.8 | 10.8 | 38 | |
| S2N22 | RBD (I/RBM) | 3–23 | Hosp. (51) | 8.4 | 919 | 38 | |
| S2N28 | RBD (I/RBM) | 3–30 | Hosp. (51) | 5.8 | 17.1 | 38 | |
| S2X128 | RBD (I/RBM) | 1–69-2 | Sympt. (75) | 23.2 | >10’000 | 38 | |
| S2X16 | RBD (I/RBM) | 1–69 | Sympt. (48) | 6.2 | >10’000 | 4,38 | |
| S2X192 | RBD (I/RBM) | 1–69 | Sympt. (75) | 223 | >10’000 | 38 | |
| S2X30 | RBD (I/RBM) | 1–69 | Sympt. (48) | 7.2 | 1750 | 38 | |
| S2X324 | RBD (I/RBM) | 2–5 | Sympt. (125) | 2.6 | 3.0 | 21 | |
| S2X58 | RBD (I/RBM) | 1–46 | Sympt. (48) | 11.1 | >10’000 | EMD-24607 | 4,38 |
| S2K146 | RBD (I/RBM) | 3–43 | Sympt. (35) | 14.2 | 12.6 | pending | 1 |
| S2H13 | RBD (I/RBM) | 3–7 | Sympt. (17) | 628 | >10’000 | 7JV4 | 4,12 |
| ADI-58125 | RBD (II) | 3–23 | SARS-CoV immune | 9.3 | 1703 | 71 | |
| S2H90 | RBD (II) | 4–61 | Sympt. (81) | 37 | >10’000 | 38 | |
| S2K63v2 | RBD (II) | 3–30 | Sympt. (118) | 129 | >10’000 | 21 | |
| S2L37 | RBD (II) | 3–13 | Hosp. (51) | 1496 | >10’000 | 21 | |
| S2X259 | RBD (II) | 1–69 | Sympt. (75) | 81.8 | 193.6 | 7RA8, 7M7W | 3 |
| S2X35 | RBD (II) | 1–18 | Sympt. (48) | 58.6 | 7999 | 7R6W | 4,12 |
| S2X219 | RBD (II) | 3–53 | Sympt. (75) | 9.8 | 268.3 | ||
| S304 | RBD (II) | 3–13 | SARS-CoV immune | 4603 | >10’000 | 7JX3 | 4,12 |
| S2A4 | RBD (II) | 3–7 | Hosp. (24) | 2285 | >10’000 | 7JVC | 12 |
| S2H97 | RBD (V) | 5–51 | Sympt. (81) | 280 | 1368 | 7M7W | 4 |
| S2L50 | NTD (i) | 4–59 | Hosp. (52) | 338 | >10’000 | 45 | |
| S2X28 | NTD (i) | 3–30 | Sympt. (48) | 423 | >10’000 | EMD-23584 | 45 |
| S2X303 | NTD (i) | 2–5 | Sympt. (125) | 4.5 | >10’000 | 7SOF, 7SOE | 9,45 |
| S2X333 | NTD (i) | 3–33 | Sympt. (125) | 13 | >10’000 | 7LXW, 7LXY | 9,40,45 |